Asensus Surgical, Inc. is a medical device company digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™. The company is focused on the development and commercialization of its Senhance® Surgical System, a multi-port robotic system, and its Intelligent Surgical Unit™ (ISU™) which provides augmented intelligence and machine vision capabilities. Asensus aims to enable consistently superior outcomes and a new standard of surgery by providing digital laparoscopy that is more intelligent, intuitive, and affordable. They are also developing the next-generation LUNA™ Surgical System.
Corporate leadership, research and development for robotic surgical systems and advanced analytics, global operational management, engineering, product testing, and surgeon training facilities.
Modern facilities within Research Triangle Park, equipped with advanced R&D labs, simulated operating environments for training and product demonstration of the Senhance Surgical System.
A dynamic and innovative environment focused on advancing surgical technology. Emphasis on collaboration, precision, and improving patient outcomes. Culture encourages problem-solving and a commitment to medical device excellence.
Serves as the central hub for Asensus Surgical's global strategy, innovation pipeline (including the LUNA Surgical System development), and U.S. commercial operations. Key to driving the vision of Performance-Guided Surgery.
Asensus Surgical supports global operations including sales, marketing, clinical support, and distribution of its Senhance Surgical System and ISU technologies across North America, Europe, Middle East, Africa (EMEA), and Asia. While primary research and development activities are centered in the US, the company maintains a global network for commercial activities and post-market surveillance to support surgeons and hospitals worldwide.
1 TW Alexander Dr, Ste 160
Durham
NC
USA
Address: Ikaros Business Park, Ikaroslaan 25, 1930 Zaventem, Belgium
To support and grow the adoption of Asensus's digital laparoscopy solutions in the EMEA region, working closely with hospitals and surgical teams.
Address: Via Caldera 21, Building F, Floor 3, 20153 Milan, Italy
To drive market penetration and provide localized support for the Senhance Surgical System in Italy.
Address: Not publicly listed, managed through Asensus Japan K.K.
To introduce and expand the use of Asensus's Performance-Guided Surgery technology in Japan, adapting to local healthcare needs and regulations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Asensus Surgical' leadership includes:
Asensus Surgical has been backed by several prominent investors over the years, including:
Asensus Surgical has strengthened its leadership team over the past year with key appointments to the Chief Operating Officer and Chief Commercial Officer roles, enhancing its operational and go-to-market capabilities. There have been no major C-suite departures publicly announced within the immediate last 12 months, though a significant technology leadership transition occurred just prior to this period.
Discover the tools Asensus Surgical uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Asensus Surgical likely utilizes common corporate email patterns for its employees. Based on standard practices and available data, the most probable format involves a combination of the employee's first initial and last name.
[first_initial][last]@asensus.com
Format
jdoe@asensus.com
Example
80%
Success rate
Asensus Surgical Investor Relations • May 9, 2024
Asensus Surgical announced its financial and operational results for Q1 2024, highlighting progress in its Senhance Surgical System program initiations and ongoing development of the LUNA Surgical System. The company also discussed its strategic priorities for the year....more
Asensus Surgical Investor Relations • February 12, 2024
Asensus Surgical appointed Satravis Watford as its new Chief Operating Officer, bringing extensive experience in operations management within the medical device industry to support the company's growth and operational efficiency....more
Asensus Surgical Investor Relations • January 8, 2024
The company provided preliminary unaudited revenue for FY2023 and outlined its 2024 strategic focus, emphasizing the development of its next-generation LUNA Surgical System and a pause on new Senhance system sales to concentrate resources....more
Asensus Surgical Investor Relations • November 6, 2023
Bretton F. Hinyard was named Chief Commercial Officer to lead Asensus Surgical's global commercial strategy and execution, aiming to expand the adoption of its surgical robotics technology....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Asensus Surgical, are just a search away.